First presentation of U.S. IDE clinical data shows statistically significant improvements in pain and function at 24 months ...
Allegheny Health Network (AHN) West Penn Hospital today announced it is the first U.S. site to participate in a ...
Ruzasvir has demonstrated highly potent and pan-genotypic antiviral activity in preclinical (picomolar range) and clinical studies. Ruzasvir has been administered to over 2,100 subjects at daily doses ...